血清MMP-2、IL-6水平对进展期胃癌患者新辅助化疗预后的影响

Effect of Serum MMP-2 and IL-6 Levels on the Prognosis of Advanced Gastric Cancer Patients With Neoadjuvant Chemotherapy

目的 观察血清基质金属蛋白酶-2(MMP-2)、白细胞介素-6(IL-6)在进展期胃癌(AGC)患者中的表达,并分析二者对新辅助化疗预后的影响。方法 选择AGC患者70例,患者均接受3个疗程的新辅助化疗,观察并记录患者治疗3个疗程的效果作为短期预后观察指标,分为预后不良组与预后良好组,调查并比较两组患者基线资料及入院时血清MMP-2、IL-6水平,分析血清MMP-2、IL-6水平对新辅助化疗预后的影响。结果 化疗3个疗程,全部70例患者中预后不良33例,占47.14%;预后不良组患者入院时血清MMP-2、IL-6水平高于预后良好组(P<0.05);经Logistic回归分析结果显示,入院时血清MMP-2、IL-6过表达是AGC患者新辅助化疗预后不良的影响因子(OR>1,P<0.05)。结论 血清MMP-2、IL-6过表达提示AGC患者新辅助化疗预后不良风险较大。

Objective To observe the expression of serum matrix metalloproteinase-2(MMP-2)and interleukin-6(IL-6)in patients with advanced gastric cancer(AGC),and to analyze their effects on the prognosis of neoadjuvant chemotherapy.Methods A total of 70 patients with AGC were selected,and all patients received 3 courses of neoadjuvant chemotherapy.The effect of 3 courses of treatment was observed and recorded as a short-term prognosis indicator,and the patients were divided into a poor prognosis group and a good prognosis group.The baseline data and serum MMP-2 and IL-6 levels of both groups were investigated and compared,and the effects of serum MMP-2 and IL-6 levels on the prognosis of neoadjuvant chemotherapy were analyzed.Results After 3 courses of chemotherapy,33 of the 70 patients had poor prognosis,accounting for 47.14%.Compared with the good prognosis group,the serum MMP-2 and IL-6 levels were higher of patients in the poor prognosis group(P1,P<0.05).Conclusion The overexpression of serum MMP-2 and IL-6 suggests that patients with AGC have a higher risk of poor prognosis after neoadjuvant chemotherapy.